This article is more than 5 years old. Information may no longer be current.

Alcon receives FDA approval for first-line use of Travatan Z

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — The U.S. Food and Drug Administration has approved Travatan Z ophthalmic solution for first-line treatment to lower IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release from Alcon, the developer of the once-daily eye drop.

"The FDA approval for first-line use of Travatan Z solution will allow eye care professionals to start newly diagnosed glaucoma and ocular hypertension patients with a product that is already well-received in the marketplace because of its efficacy and safety," Stuart Raetzman, Alcon's vice president of global marketing and area president for the United States, said in the release. "This approval also means that Travatan Z will be the first and only prostaglandin analogue approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride (BAK)."

Travatan Z (travoprost ophthalmic solution 0.004%) with the preservative system sofZia was first introduced in the U.S. in 2006.